Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic oesophageal cancer

ESMO World Congress on Gastrointestinal Cancer 2021

30 Jun - 3 Jul 2021

Published: 12 Jul 2021

Views: 1637

Rating:

Save

Dr Zev Wainberg - University of California Los Angeles, California, USA

Dr Zev Wainberg speaks to ecancer about the phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic oesophageal cancer. Initially, he explains the background of the study.

He then, discusses the methodology and results of this study.

Dr Wainberg concludes, saying that tiragolumab combined with atezolizumab was well-tolerated with an acceptable safety profile, and showed preliminary anti-tumour activity in heavily pretreated patients with metastatic oesophageal cancers not previously treated with cancer immunotherapy.

Related Videos

Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery

Dr Michael Foote - Memorial Sloan Kettering Cancer Center, New York, USA

Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery ( Dr Michael Foote - Memorial Sloan Kettering Cancer Center, New York, USA )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Immunotherapy significantly increases the number of patients free from bowel cancer

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK

Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )

More from ecancer